Malinka Jansson
Agilent Technologies (United States) · 13 works · 2,311 citations · h-index 6
Top works
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
- Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
- Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Head and Neck Squamous Cell Carcinoma
- PD-L1 IHC 22C3 pharmDx Demonstrates Precision and Reproducibility in Triple-negative Breast Cancer
- Assay performance of the PD-L1 IHC 28-8 pharmDx assay in squamous cell carcinoma of the head and neck (SCCHN).
- PD-L1 IHC 22C3 pharmdx demonstrates precision and reproducibility in detecting PD-L1 expression in triple negative breast cancer.
- Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38.
- Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.
- Development of a diagnostic PD-L1 immunohistochemical assay for nivolumab therapy in urothelial carcinoma.
- Development of an immunohistochemistry assay for PD-L1 for using the 22C3 antibody in melanoma.